$261,32M | |
$2,57 | |
$99,95 | |
$0,91 | |
$2,67 | |
-- | |
0,00% | |
1M |
Editas Medicine, Inc. (EDIT) is currently trading at $2,67 as of null, reflecting a 0,00% move ($-0,00) from the previous close.
In the short term, the stock has returned +40,90% over the past four weeks. Over the last 12 months, Editas Medicine, Inc. has recorded a +138,39% price change, indicating a strong performance relative to the broader market.
Over the past seven days, Editas Medicine, Inc. has traded within a short-term range shaped by market sentiment in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. During this period, the stock moved from its previous closing price of $2,23 to the latest recorded price of $2,67, reflecting an intraday change of 0,00%. Daily movements highlight shifts in trading volume (1 125 211,508628), investor positioning, and reactions to macroeconomic updates.
From a momentum standpoint, EDIT has delivered a +40,90% return over the past month and a +138,39% change in the last 12 months, indicating a strong trend relative to its broader sector peers.
You can buy and trade EDIT on MEXC in three simple steps:
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary ene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 87 |
| Sector | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Company Website |
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Amount
1 EDIT = 2,67 USD